Back
The Duckhorn Portfolio Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Buy
70
NAPA
The Duckhorn Portfolio
Last Price:
10.98
Seasonality Move:
-0.87%
Sell
35
ALNY
Alnylam Pharmaceuticals
Last Price:
270.01
Seasonality Move:
13.19%
Buy
70
The Duckhorn Portfolio (NAPA)
is a Buy
Is The Duckhorn Portfolio a Buy, Sell or Hold?
- The current The Duckhorn Portfolio [NAPA] share price is $10.97. The Score for NAPA is 70, which is 40% above its historic median score of 50, and infers lower risk than normal.
- NAPA is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
35
Alnylam Pharmaceuticals (ALNY)
is a Sell
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
- The current Alnylam Pharmaceuticals [ALNY] share price is $273.91. The Score for ALNY is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.
- ALNY is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
NAPA Stock Price Chart
What is The Duckhorn Portfolio's stock price today?
-
The The Duckhorn Portfolio share price today is $10.97
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and NAPA is experiencing slight buying pressure.
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $273.91
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and ALNY is experiencing buying pressure, which is a positive indicator for future bullish movement.
NAPA Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.96 | Buy |
| Relative Strength Index (14 RSI): | 84.5 | Buy |
| Chaikin Money Flow: | 0 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (7.39 - 11.97) | Buy |
| Bollinger Bands (100): | (5.68 - 9.26) | Buy |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 1.53 | Buy |
| Relative Strength Index (14 RSI): | 44.14 | Sell |
| Chaikin Money Flow: | 854887 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (270.99 - 291.37) | Sell |
| Bollinger Bands (100): | (223 - 289.2) | Buy |
NAPA Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 10.97 | Buy |
| 20-day SMA: | 10.69 | Buy |
| 50-day SMA: | 7.85 | Buy |
| 200-day SMA: | 8.06 | Buy |
| 8-day EMA: | 10.92 | Buy |
| 20-day EMA: | 10.19 | Buy |
| 50-day EMA: | 8.74 | Buy |
| 200-day EMA: | 8.47 | Buy |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 283.39 | Sell |
| 20-day SMA: | 283.12 | Sell |
| 50-day SMA: | 274.41 | Sell |
| 200-day SMA: | 205.7 | Buy |
| 8-day EMA: | 280.46 | Sell |
| 20-day EMA: | 281.6 | Sell |
| 50-day EMA: | 272.95 | Buy |
| 200-day EMA: | 226.73 | Buy |
The Duckhorn Portfolio Earnings Growth & NAPA Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.02 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.09 per share, and an increase next year of $0.08 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.86 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.48 per share, and an increase next year of $0.66 per share.
The Duckhorn Portfolio Technical Analysis
| Oct 21 | Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | Oct 30 | Oct 31 | Nov 1 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 21 | 22 | 23 | 24 | 25 | 28 | 29 | 30 | 31 | 01 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Oct 21 | Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | Oct 30 | Oct 31 | Nov 1 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 21 | 22 | 23 | 24 | 25 | 28 | 29 | 30 | 31 | 01 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||